PacBio Files Automatic Mixed Securities Shelf
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PACB?
PacBio files automatic mixed securities shelf
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PACB
Wall Street analysts forecast PACB stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.680
Low
2.00
Averages
2.40
High
3.00
Current: 1.680
Low
2.00
Averages
2.40
High
3.00
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PacBio Partners with DNAstack to Enable Global Genomic Data Sharing
- Global Data Sharing Platform: PacBio's collaboration with DNAstack introduces the world's first federated platform for HiFi whole genome sequencing data, enabling secure international research among 30 clinical and research institutions across 15 countries, significantly enhancing global collaboration in rare disease research.
- Data Privacy Protection: The platform allows researchers to query and analyze data without centralizing protected information, ensuring compliance with regional data privacy regulations, thereby facilitating global collaboration while safeguarding participant privacy.
- Enhanced Technological Advantage: The high accuracy and completeness of HiFi whole genome sequencing empower researchers to confidently detect complex variants, and when combined with federated data sharing, it significantly accelerates understanding and discovery of rare diseases, aiding clinical research.
- Rapidly Growing Collaborative Network: Since its inception in 2023, the HiFi Solves Global Consortium has nearly doubled in size, reflecting the increasing global demand for privacy-preserving genomic research models, with plans to connect over 10,000 HiFi whole genome sequences, forming one of the largest datasets dedicated to rare disease research.
See More
Pacific Biosciences COO Sells Shares
- Executive Sell-off: On February 17, 2026, Pacific Biosciences COO Mark Van Oene sold 184,897 shares, which may raise concerns about the company's future performance, as executive sell-offs are often perceived as negative signals regarding company outlook.
- Market Reaction: Such sell-off actions could lead to a decline in investor confidence, potentially impacting stock price performance, especially in the biotech sector where market sensitivity to executive trades is high, possibly exacerbating stock price volatility.
- Shareholding Structure Change: Following this sell-off, the company's shareholder structure may change, prompting investors to monitor upcoming shareholder meetings and management's further statements to assess the stability of corporate governance.
- Strategic Implications: The executive sell-off may trigger a reassessment of the company's strategic direction, leading investors to question the long-term growth potential, which could subsequently affect its performance in the capital markets.
See More
PacBio (PACB) Q4 2025 Earnings Call Transcript
See More
Pacific Biosciences Set to Announce Q4 Earnings on February 12
- Earnings Announcement: Pacific Biosciences (PACB) is set to release its Q4 earnings on February 12, with a consensus EPS estimate of -$0.13, reflecting a 35% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $42.79 million, representing a 9.2% year-over-year increase, suggesting stable growth in market demand that could bolster investor confidence moving forward.
- Historical Performance Review: Over the past two years, PACB has beaten EPS estimates 88% of the time, although it has only surpassed revenue estimates 38% of the time, indicating a relatively stable performance in profitability but a need for improvement in revenue growth.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates have experienced three upward revisions and two downward adjustments, reflecting market divergence and uncertainty regarding the company's future performance.
See More
PacBio Completes Sale of Short-Read DNA Technology Assets
- Asset Sale Completion: PacBio completed the sale of short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash proceeds, aimed at strengthening its balance sheet and refocusing on long-read sequencing development.
- Strategic Shift: In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform, reallocating resources to innovations in the long-read sequencing market, which is expected to enhance its market share.
- Accelerated Technology Development: The transaction enables PacBio to expedite the development of SPRQ-Nx chemistry, which will be launched globally at a competitive pricing structure, providing a more comprehensive view of the genome and further solidifying its leadership in genomic sequencing.
- Future Growth Potential: The CEO of PacBio stated that this transaction not only strengthens the company's balance sheet but also lays the groundwork for the next phase of growth, expected to drive the adoption of its differentiated long-read sequencing platform and enhance market competitiveness.
See More
Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
See More
PacBio Partners with DNAstack to Enable Global Genomic Data Sharing
- Global Data Sharing Platform: PacBio's collaboration with DNAstack introduces the world's first federated platform for HiFi whole genome sequencing data, enabling secure international research among 30 clinical and research institutions across 15 countries, significantly enhancing global collaboration in rare disease research.
- Data Privacy Protection: The platform allows researchers to query and analyze data without centralizing protected information, ensuring compliance with regional data privacy regulations, thereby facilitating global collaboration while safeguarding participant privacy.
- Enhanced Technological Advantage: The high accuracy and completeness of HiFi whole genome sequencing empower researchers to confidently detect complex variants, and when combined with federated data sharing, it significantly accelerates understanding and discovery of rare diseases, aiding clinical research.
- Rapidly Growing Collaborative Network: Since its inception in 2023, the HiFi Solves Global Consortium has nearly doubled in size, reflecting the increasing global demand for privacy-preserving genomic research models, with plans to connect over 10,000 HiFi whole genome sequences, forming one of the largest datasets dedicated to rare disease research.
See More
Pacific Biosciences COO Sells Shares
- Executive Sell-off: On February 17, 2026, Pacific Biosciences COO Mark Van Oene sold 184,897 shares, which may raise concerns about the company's future performance, as executive sell-offs are often perceived as negative signals regarding company outlook.
- Market Reaction: Such sell-off actions could lead to a decline in investor confidence, potentially impacting stock price performance, especially in the biotech sector where market sensitivity to executive trades is high, possibly exacerbating stock price volatility.
- Shareholding Structure Change: Following this sell-off, the company's shareholder structure may change, prompting investors to monitor upcoming shareholder meetings and management's further statements to assess the stability of corporate governance.
- Strategic Implications: The executive sell-off may trigger a reassessment of the company's strategic direction, leading investors to question the long-term growth potential, which could subsequently affect its performance in the capital markets.
See More
PacBio (PACB) Q4 2025 Earnings Call Transcript
See More
Pacific Biosciences Set to Announce Q4 Earnings on February 12
- Earnings Announcement: Pacific Biosciences (PACB) is set to release its Q4 earnings on February 12, with a consensus EPS estimate of -$0.13, reflecting a 35% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $42.79 million, representing a 9.2% year-over-year increase, suggesting stable growth in market demand that could bolster investor confidence moving forward.
- Historical Performance Review: Over the past two years, PACB has beaten EPS estimates 88% of the time, although it has only surpassed revenue estimates 38% of the time, indicating a relatively stable performance in profitability but a need for improvement in revenue growth.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates have experienced three upward revisions and two downward adjustments, reflecting market divergence and uncertainty regarding the company's future performance.
See More
PacBio Completes Sale of Short-Read DNA Technology Assets
- Asset Sale Completion: PacBio completed the sale of short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash proceeds, aimed at strengthening its balance sheet and refocusing on long-read sequencing development.
- Strategic Shift: In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform, reallocating resources to innovations in the long-read sequencing market, which is expected to enhance its market share.
- Accelerated Technology Development: The transaction enables PacBio to expedite the development of SPRQ-Nx chemistry, which will be launched globally at a competitive pricing structure, providing a more comprehensive view of the genome and further solidifying its leadership in genomic sequencing.
- Future Growth Potential: The CEO of PacBio stated that this transaction not only strengthens the company's balance sheet but also lays the groundwork for the next phase of growth, expected to drive the adoption of its differentiated long-read sequencing platform and enhance market competitiveness.
See More
Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.
See More
